Company Insights

RIGL customer relationships

Explore interactive graphBrowse insights index
RIGL customer relationship map

Rigel Pharmaceuticals (RIGL): Customer map, concentration risk, and commercial posture

Rigel Pharmaceuticals discovers and develops small‑molecule therapies and monetizes primarily through product sales in the U.S., commercial license agreements with regional partners, and royalties/milestones from out‑licensing deals. Its operating model combines direct commercialization (U.S. specialty product sales) with heavy dependence on specialty distributors and regional partners to scale international reach and supply obligations. For investors, customer concentration and partnered commercialization are the structural drivers of both revenue volatility and upside from milestone streams.

If you want a consolidated view of corporate customer exposures and partner clauses, start here: https://nullexposure.com/

Why customers and partners determine the investment thesis

Rigel’s revenue mix is not broad retail: a handful of distributors and commercialization partners account for a material share of net product sales, and Rigel retains manufacturing and supply responsibilities for several partnered programs. That combination amplifies commercial leverage (high upside when top customers perform) and counterparty risk (a small number of wholesalers can drive meaningful revenue swings). The company is also actively licensing territory rights to offset commercialization cost and capture upfront/milestone economics.

Explore structured coverage of partner risk and customer concentration on our homepage: https://nullexposure.com/

Relationship catalog — each named partner and what they mean for RIGL

McKesson Corporation

Rigel reported that McKesson accounted for 45% of net product sales in FY2024, making McKesson the single largest customer by far and a strategic distribution channel for Rigel’s marketed products. This data is drawn from Rigel’s FY2024 Form 10‑K and the company’s customer concentration disclosure.

Cencora Inc. (formerly ASD Healthcare)

Cencora represented 20% of net product sales in FY2024, making it a top‑tier specialty distributor for Rigel’s products and a material revenue source. The FY2024 Form 10‑K lists Cencora (formerly ASD) as accounting for 20% of sales.

Cardinal Health, Inc. (listed as Cardinal Health / CAH)

Cardinal Health accounted for 13% of net product sales in FY2024, signaling that Cardinal is also a major distributor relationship for the company’s commercial footprint in specialty channels. This percentage is disclosed in the FY2024 Form 10‑K.

McKesson Specialty Care Distribution Corporation

McKesson Specialty Care Distribution Corporation is specifically called out in the 10‑K as a customer concentration risk member, confirming McKesson’s role across Rigel’s specialty distribution network. The 10‑K includes McKesson Specialty Care in its customer concentration disclosures.

Cencora Inc (COR) — duplicate entry in filings

The filing also references Cencora by its corporate name and ticker; this reiteration in the Form 10‑K underscores the materiality and consistency of Cencora’s contribution to Rigel’s revenue base. See the FY2024 Form 10‑K customer table for the repeated disclosure.

Cardinal Health Inc (CAH) — duplicate filing reference

Cardinal appears in multiple line items and tagging within the 10‑K, which reinforces Cardinal’s status as a core distributor in Rigel’s commercial channel architecture. The FY2024 10‑K includes Cardinal as a >10% customer.

Kissei / Kissei Pharmaceutical (KSPHF)

Kissei accounted for 11% of Rigel’s net product sales in FY2024 and holds licensed development and commercialization rights in parts of Asia, with Rigel retaining supply obligations. The FY2024 Form 10‑K reports Kissei at 11%, and press coverage documents Kissei’s regional rights secured in 2018.

AstraZeneca (AZN)

AstraZeneca holds an exclusive license for an oral rheumatoid arthritis candidate from Rigel and is responsible for development and commercialization under that agreement; Rigel receives royalties and milestone payments under the license. This arrangement is summarized in a March 2026 earnings preview and reflects Rigel’s out‑licensing strategy.

Eli Lilly (LLY)

Rigel is partnered with Eli Lilly on ocadusertib, a RIPK1 inhibitor; Rigel is eligible for milestone payments and royalties under the development collaboration reported in market commentary in early 2026. The partnership represents potential non‑product revenue upside if clinical progress triggers milestones.

Onco360

Onco360 was selected by Rigel as a limited‑distribution specialty pharmacy partner for TAVALISSE, GAVRETO, and REZLIDHIA, positioning Onco360 as a controlled channel for high‑touch oncology and specialty products. This selection was announced in a January 2026 press release.

Annora Pharma Private Ltd.

Rigel entered a settlement with Annora (and related parties) resolving patent litigation around TAVALISSE and granting Annora a license to sell a generic product no earlier than Q2 2032 under defined terms, per Rigel’s March 2026 press release. The agreement formalizes future generic entry timing and licensing economics.

Hetero Labs Ltd.

Hetero Labs is a counterparty in the same settlement that grants a limited license to commercialize a generic TAVALISSE product under specific conditions, as disclosed in Rigel’s March 2026 PR Newswire release resolving the patent litigation.

Hetero USA, Inc.

Hetero USA, Inc. is included in the March 2026 settlement with Rigel and will be subject to the licensing timetable that governs generic entry for TAVALISSE. The PR Newswire notice details the parties and license effective timing.

Constraints and operational characteristics that structure risk and upside

  • Geography and go‑to‑market: Rigel commercializes products in the U.S. and uses third‑party commercialization agreements for ex‑U.S. markets, indicating a U.S.‑centric revenue footprint with outsourced international commercialization (company disclosure).
  • Materiality of marketed products: The company states that a significant portion of value depends on sustaining U.S. commercialization, making current products central to valuation and near‑term cash flow (company disclosure).
  • Distributor posture and concentration: Rigel’s specialty distributors resell products to specialty pharmacies, providers and hospitals, and the FY2024 customer table shows that a small number of distributors (McKesson, Cencora, Cardinal) account for a very large share of net sales — high concentration that increases counterparty risk.
  • Licensing and partner economics: Rigel uses commercialization license agreements (for example, the Grifols agreement described in filings) to realize upfront payments, milestones and stepped royalties, which is a deliberate monetization pattern to de‑risk development and expand reach.
  • Manufacturing and supply obligations: Rigel remains responsible for the manufacture and supply of certain partnered products (the filings explicitly name Kissei for supply obligations); that makes Rigel both a licensor and a critical supplier to partners, concentrating operational risk in manufacturing capability and quality control.
  • Relationship maturity and stage: Several partnerships are active commercial relationships (e.g., GAVRETO commercialization began in mid‑2024) and settlements define long‑dated patent exclusivity assumptions (e.g., TAVALISSE generic licensing timetable through 2032).

Concentration, contracting posture, and what to watch next

The headline for investors is straightforward: Rigel’s revenue and operational exposure are concentrated among a few distributors and regional partners, while upside comes from milestone-bearing licenses. Key monitorables include McKesson and Cencora buying patterns, the commercial performance of GAVRETO and TAVALISSE in limited distribution, and milestone triggers from partners such as AstraZeneca and Eli Lilly. The March 2026 settlement with Annora/Hetero clarifies generic timing for TAVALISSE and removes a headline litigation overhang through 2032, but it also establishes a path to eventual generic competition that investors must model.

For a practical readout of partner clauses and concentration metrics, get detailed partner exposure analysis: https://nullexposure.com/

Bottom line for investors

  • Positive: Robust partnerships convert development into near‑term cash (upfronts, milestones, royalties) while specialty distributors deliver scaled U.S. sales.
  • Risk: Heavy customer concentration (McKesson 45%, Cencora 20%, Cardinal 13% in FY2024) and manufacturing/supply responsibilities increase revenue and operational concentration risk.
  • Actionable: Track distributor purchase trends, milestone timelines for AstraZeneca/Eli Lilly programs, and the commercial uptake of limited‑distribution products to judge sustainability of current margins and growth.

If you need a focused briefing or bespoke exposure report on Rigel’s partner contracts and counterparty risk, start here: https://nullexposure.com/